Display options
Cite
Radosavljevic-Radovanovic M, Radovanovic N, Vasiljevic Z, et al. Usefulness of NT-proBNP in the Follow-Up of Patients after Myocardial Infarction. J Med Biochem. 2016;35(2):158-165doi: 10.1515/jomb-2016-0003.
Radosavljevic-Radovanovic, M., Radovanovic, N., Vasiljevic, Z., Marinkovic, J., Mitrovic, P., Mrdovic, I., Stankovic, S., Kružliak, P., Beleslin, B., Uscumlic, A., & Kostic, J. (2016). Usefulness of NT-proBNP in the Follow-Up of Patients after Myocardial Infarction. Journal of medical biochemistry, 35(2), 158-165. https://doi.org/10.1515/jomb-2016-0003
Radosavljevic-Radovanovic, Mina, et al. "Usefulness of NT-proBNP in the Follow-Up of Patients after Myocardial Infarction." Journal of medical biochemistry vol. 35,2 (2016): 158-165. doi: https://doi.org/10.1515/jomb-2016-0003
Radosavljevic-Radovanovic M, Radovanovic N, Vasiljevic Z, Marinkovic J, Mitrovic P, Mrdovic I, Stankovic S, Kružliak P, Beleslin B, Uscumlic A, Kostic J. Usefulness of NT-proBNP in the Follow-Up of Patients after Myocardial Infarction. J Med Biochem. 2016 Apr;35(2):158-165. doi: 10.1515/jomb-2016-0003. Epub 2016 May 09. PMID: 28356876; PMCID: PMC5346793.
Copy Download .nbib Format: NLM
Share it on

J Med Biochem. 2016 Apr;35(2):158-165. doi: 10.1515/jomb-2016-0003. Epub 2016 May 09.

Usefulness of NT-proBNP in the Follow-Up of Patients after Myocardial Infarction.

Journal of medical biochemistry

Mina Radosavljevic-Radovanovic, Nebojsa Radovanovic, Zorana Vasiljevic, Jelena Marinkovic, Predrag Mitrovic, Igor Mrdovic, Sanja Stankovic, Peter Kružliak, Branko Beleslin, Ana Uscumlic, Jelena Kostic

Affiliations

  1. Cardiology Clinic, Clinical Center of Serbia and Medical School, University of Belgrade.
  2. Institute of Statistics, Medical School, University of Belgrade, Belgrade, Serbia.
  3. Centre of Medical Biochemistry, Clinical Center of Serbia, Belgrade, Serbia.
  4. International Clinical Research Center, St Anne's University Hospital, Brno, Czech Republic.
  5. Cardiology Clinic, Clinical Center of Serbia, Belgrade, Serbia.

PMID: 28356876 PMCID: PMC5346793 DOI: 10.1515/jomb-2016-0003

Abstract

BACKGROUND: Since serial analyses of NT-proBNP in patients with acute coronary syndromes have shown that levels measured during a chronic, later phase are a better predictor of prognosis and indicator of left ventricular function than the levels measured during an acute phase, we sought to assess the association of NT-proBNP, measured 6 months after acute myocardial infarction (AMI), with traditional risk factors, characteristics of in-hospital and early postinfarction course, as well as its prognostic value and optimal cut-points in the ensuing 1-year follow-up.

METHODS: Fasting venous blood samples were drawn from 100 ambulatory patients and NT-proBNP concentrations in lithium-heparin plasma were determined using a one-step enzyme immunoassay based on the »sandwich« principle on a Dimension RxL clinical chemistry system (DADE Behring-Siemens). Patients were followed-up for the next 1 year, for the occurrence of new cardiac events.

RESULTS: Median (IQR) level of NT-proBNP was 521 (335-1095) pg/mL. Highest values were mostly associated with cardiac events during the first 6 months after AMI. Negative association with reperfusion therapy for index infarction confirmed its long-term beneficial effect. In the next one-year follow-up of stable patients, multivariate Cox regression analysis revealed the independent prognostic value of NT-proBNP for new-onset heart failure prediction (p=0.014), as well as for new coronary events prediction (p=0.035). Calculation of the AUCs revealed the optimal NT-proBNP cut-points of 800 pg/mL and 516 pg/mL, respectively.

CONCLUSIONS: NT-proBNP values 6 months after AMI are mainly associated with the characteristics of early infarction and postinfarction course and can predict new cardiac events in the next one-year follow-up.

Keywords: N-terminal pro-brain natriuretic peptide; myocardial infarction; postinfarction period; prognostic neurohumoral testing

Conflict of interest statement

The authors stated that they have no conflicts of interest regarding the publication of this article.

References

  1. J Histochem Cytochem. 2002 Jun;50(6):799-809 - PubMed
  2. J Am Coll Cardiol. 2007 Jul 17;50(3):205-14 - PubMed
  3. JAMA. 2004 Sep 15;292(11):1307-16 - PubMed
  4. J Am Coll Cardiol. 2005 Feb 15;45(4):533-41 - PubMed
  5. J Am Heart Assoc. 2014 Jul 22;3(4):null - PubMed
  6. N Engl J Med. 2001 Oct 4;345(14):1014-21 - PubMed
  7. Circulation. 2006 Jul 18;114(3):201-8 - PubMed
  8. Circulation. 2012 Jan 3;125(1):e2-e220 - PubMed
  9. Peptides. 2014 Feb;52:143-8 - PubMed
  10. Am J Cardiol. 2008 Feb 4;101(3A):61-6 - PubMed
  11. Eur Heart J. 2008 Mar;29(6):748-56 - PubMed
  12. J Am Coll Cardiol. 2006 Jan 3;47(1):52-60 - PubMed
  13. Dis Markers. 2013;34(3):199-204 - PubMed
  14. JAMA. 2009 Jul 1;302(1):49-57 - PubMed
  15. N Engl J Med. 2002 Jul 18;347(3):161-7 - PubMed
  16. Rev Cardiovasc Med. 2013;14(2-4):e92-8 - PubMed
  17. PLoS One. 2015 Jan 28;10(1):e0117143 - PubMed
  18. Eur Heart J. 2012 Aug;33(16):2001-6 - PubMed
  19. Heart. 2006 Jul;92(7):916-20 - PubMed
  20. J Am Soc Echocardiogr. 2004 Oct;17 (10 ):1086-119 - PubMed
  21. FASEB J. 2003 Jun;17(9):1105-7 - PubMed
  22. Am J Med. 2008 Jan;121(1):50-7 - PubMed
  23. Am Heart J. 2006 Mar;151(3):712.e1-712.e7 - PubMed
  24. FASEB J. 2004 Dec;18(15):1928-30 - PubMed
  25. Int J Cardiol. 2003 Oct;91(2-3):193-200 - PubMed

Publication Types